Definium Therapeutics Overview
Definium Therapeutics Target Price
Analysts' average 12-month price target for Definium Therapeutics is $53.
Get informed when a big investor buys or sells
+ FollowShare Price
$42.79
Average Target Price
$53.08
24.1% upside
24.1% upside12 analysts in the last 4 months
High: $73 | Low: $30
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-07-27 | Wells FargoBenjamin Burnett | $68 | 58.9% upside |  |
| 2026-07-24 | Piper Sandler | $73 | 70.6% upside | |
| 2026-07-08 | Stifel Nicolaus | $60 | 40.2% upside | |
| 2026-06-30 | Canaccord Genuity | $58 | 35.5% upside | |
| 2026-06-23 | NeedhamAmi Fadia | $50 | 16.8% upside | |
| 2026-06-22 | Canaccord Genuity | $60 | 40.2% upside | |
| 2026-06-22 | Oppenheimer | $60 | 40.2% upside | |
| 2026-06-22 | Leerink PartnersMarc Goodman | $52 | 21.5% upside | |
| 2026-05-08 | Piper SandlerDavid Amsellem | $48 | 12.2% upside | |
| 2026-04-23 | Oppenheimer | $40 |  6.5% downside | |
| 2026-04-16 | Stifel NicolausPaul Matteis | $30 | 29.9% downside | |
| 2026-04-16 | Canaccord GenuitySumant Kulkarni | $38 | 11.2% downside | |
| 2026-04-10 | Piper Sandler | $49 | 14.5% upside | |
| 2026-02-23 | Wolfe Research | $25 | 41.6% downside | |
| 2026-01-29 | Jefferies | $30 | 29.9% downside | |
| 2026-01-29 | Robert W. Baird | $37 | 13.5% downside | |
| 2026-01-23 | RBC Capital | $36 | 15.9% downside | |
| 2025-10-13 | NeedhamAmi Fadia | $28 | 34.6% downside | |
| 2025-03-07 | Robert W. Baird | $16 | 62.6% downside | |
| 2024-09-16 | Canaccord GenuitySumart Kulkami | $14 | 67.3% downside | |
| 2024-06-05 | RBC CapitalBrian Abrahams | $22 | 48.6% downside | |
| 2024-05-13 | OppenheimerFrancois Brisebois | $20 | 53.3% downside | |
| 2022-11-16 | RBC Capital | $5 | 88.3% downside | |